医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FINEOS Capabilities Recognised in Report on Unclaimed Death Benefits

2014年02月21日 AM12:10
このエントリーをはてなブックマークに追加


 

DUBLIN

FINEOS Corporation, a market leading provider of Group Life and Health claims management software, announced today that it has been profiled in the latest report from the Aite Group, “Unclaimed Death Benefits: Technology Aspirin for a Big Headache1, The report examines the problems facing life insurers as they deal with the issue of unclaimed death benefits, an area that has come increasingly into focus as US states introduce more onerous requirements for notifying beneficiaries and paying out death benefits. Problems with wrong and missing data in the life insurers’ records and in the Social Security Death Master File have compounded the situation and life insurers now find themselves exposed to significant liability.

The report analyses and summarises the capabilities of solution providers to help life insurers with accurate death-record matching and effective beneficiary research and outreach capabilities. 16 companies were profiled in the report which concluded that FINEOS “supports the widest range of products, including long-term products, along with a system originally designed with a customer-centric data model and a component architecture approach and a good list of reference customers among US life insurers. For life insurers that operate internationally, FINEOS also offers best-of-breed claims capabilities in multiple, non-US geographies”.

According to Todd Eyler, Senior Analyst with the Aite Group, “FINEOS offers one of the most mature solutions in this area for US life insurers. Not only is it a leading specialist in the core claims system domain but the company has demonstrated it can implement FINEOS Claims for Life Insurance in multiple geographies. FINEOS Claims’ depth of functionality makes it an attractive system for all life insurers looking to invest in a new claims system.”

Commenting on the new report Michael Kelly, CEO, FINEOS Corporation said, “We are pleased to be featured in this report from the Aite Group. It’s a testament to the functional breadth of FINEOS Claims for Life Insurance and the innovative ways in which our customers have collaborated with us to achieve their business goals.”

FINEOS is the leading claims solution for the global Life and Health insurance industry and supports the processing of Life, Disability, Critical Illness, AD&D, Waiver and a number of related lines. FINEOS supports both group and individual business claims on a single platform and can be used by organisations of all sizes, from small departmental claims teams to very large teams with thousands of users and millions of claims. FINEOS currently works with 50 insurance carriers and counts six of the top 20 Life & Health carriers in the US and four of the top Life & Health carriers in Australia as customers. It is the global leader for Government Accident Compensation schemes, processing 100% of accident claims in New Zealand.

1Unclaimed Death Benefits: Technology Aspirin for a Big Headache”, Aite Group, 2014

About FINEOS Corporation

FINEOS is a market leading provider of core software solutions for Insurance and Government Accident Compensation Insurance. Our flagship product, FINEOS Claims, is the insurance industry’s best-in-class solution for all, Life, Disability and Accident Compensation claims. Established in 1993, the company delivers innovative solutions to a global market and has customers, employees and established bases in North America, Europe, Africa and the Asia Pacific markets. For more information, visit www.FINEOS.com

###

CONTACT

FINEOS Corporation
Susanne Ryan
VP Marketing
+ 353 1 639
9918
susanne.ryan@FINEOS.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続